A guest post from Patent Docs.
The Biotechnology Innovation Organization (BIO) will be holding its fourth annual IP & Diagnostics Symposium from 8:15 am to 2:30 pm on September 29, 2016 at the Hilton Alexandria Old Town Hotel in Alexandria, VA. The Symposium will review and evaluate the state of patent law for advanced molecular diagnostics and personalized medicine as well as explore the implications of developments in these fields for patenting in the broader biopharma sector.
The Symposium will offer the following presentations and sessions:
• Session 1 — Diagnostic Tests – Is There Anything Left to Patent? — Warren Woessner of Schwegman, Lundberg & Woessner, P.A. will moderate a panel consisting of Leslie Fischer, Novartis; and Hans Sauer, Biotechnology Innovation Organization.
• Session 2 — Patenting Diagnostics and Personalized Medicine in Europe and Beyond — Berthold Rutz of the European Patent Office will moderate a panel consisting of Jennifer Enmon of Vossius & Partner; and Arti Rai, Elvin R. Latty Professor of Law and co-Director, Duke Law Center for Innovation Policy, Duke University.
• Session 3 — How Diagnostics can be Developed in a Post-Mayo World —Patent Docs author Donald Zuhn of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Michael Flavin of Flavin Ventures; and Patent Docs author Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP (session sponsored by McDonnell Boehnen Hulbert & Berghoff LLP).
• Session 4 (Working Luncheon) — Regulation of Diagnostics: Trends and Developments — Scott Danzis of Covington & Burling LLP will moderate a panel consisting of Wade Ackerman of Covington & Burling LLP.
An agenda for the Symposium, including a list of speakers, moderators, and panelists can be obtained here.
The registration fee for the Symposium is $70-90 (service provider rates), $40-50 (in-house counsel at R&D company rates), or $0 (academic, government & non-profit association rates). See the registration details here.